Hepatitis C is a blood-borne viral infection which can, over decades, lead to liver fibrosis (scarring), and in some patients, cirrhosis. It is transmitted through blood-to-blood contact, and in rare cases, sexual transmission. Approximately 4 million Americans have chronic hepatitis C; however, only 25 to 30% have been diagnosed. The diagnosis is made by specific laboratory (blood) testing. Liver biopsy may be recommended to assess the degree of fibrosis and need for treatment.
Previously treatment included pegylated Interferon and Ribavirin, which resulted in viral clearance in approximately 60% of those patients treated. In 2011 two new medications were added to standard hepatitis C treatment; both drugs are protease inhibitors and they are manufactured by different companies. One is called Victrelis (boceprevir) and the other is called Incivek (telaprevir). Patients who are treated with one of these two new drugs will continue to take Interferon and Ribavirin; it is hoped that with the addition of these treatments will lead to increased viral clearance rates.
This site includes links to files you can view online or print. To download and print information, you will need the latest version of Adobe Acrobat Reader. Download it free.
